HCW11-006
Not Specified (In Vivo Applications)
Not DisclosedLicensed to Beijing Trimmune
Key Facts
Indication
Not Specified (In Vivo Applications)
Phase
Not Disclosed
Status
Licensed to Beijing Trimmune
Company
About HCW Biologics
HCW Biologics is developing a novel class of fusion immunotherapies targeting the interconnected biology of chronic inflammation and aging. Founded by Dr. Hing C. Wong, whose prior discovery led to the FDA-approved immunotherapy Anktiva, the company leverages two proprietary protein engineering platforms to create multi-functional biologics. Its strategy encompasses advancing internal clinical candidates while also commercializing platform-derived reagents for next-generation cell therapy manufacturing, aiming to create value through both therapeutic development and strategic partnerships.
View full company profile